Filtered By:
Source: European Heart Journal
Education: Study
Therapy: Statin Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 9 results found since Jan 2013.

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract
ConclusionLong-term statin treatment is remarkably safe with a low risk of clinically relevant adverse effects as defined above; statin-associated muscle symptoms were discussed in a previous Consensus Statement. Importantly, the established cardiovascular benefits of statin therapy far outweigh the risk of adverse effects.
Source: European Heart Journal - April 27, 2018 Category: Cardiology Source Type: research

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study
Conclusion Five years' primary prevention treatment of middle-aged men with a statin significantly reduces healthcare resource utilization, is cost saving, and increases QALYs. Treatment of even younger, lower risk individuals is likely to be cost-effective.
Source: European Heart Journal - February 1, 2014 Category: Cardiology Authors: McConnachie, A., Walker, A., Robertson, M., Marchbank, L., Peacock, J., Packard, C. J., Cobbe, S. M., Ford, I. Tags: Prevention and epidemiology Source Type: research

Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry
Conclusion Among patients with PAD in the REACH registry, statin use was associated with an ~18% lower rate of adverse limb outcomes, including worsening symptoms, peripheral revascularization, and ischaemic amputations. These findings suggest that statin therapy not only reduces the risk of adverse cardiovascular events, but also favourably affects limb prognosis in patients with PAD.
Source: European Heart Journal - November 1, 2014 Category: Cardiology Authors: Kumbhani, D. J., Steg, P. G., Cannon, C. P., Eagle, K. A., Smith, S. C., Goto, S., Ohman, E. M., Elbez, Y., Sritara, P., Baumgartner, I., Banerjee, S., Creager, M. A., Bhatt, D. L., on Behalf of the REACH Registry Investigators Tags: Vascular medicine Source Type: research

Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry)
Conclusion In this 1-year follow-up analysis of the EORP-AF pilot general registry, we provide data on the first contemporary registry focused on management practices among European cardiologists, conducted since the publication of the new ESC guidelines. Overall OAC use remains high, although persistence with therapy may be problematic. Nonetheless, continued OAC use was more common than in prior reports. Despite the high prescription of OAC, 1-year mortality and morbidity remain high in AF patients, particularly from heart failure and hospitalizations.
Source: European Heart Journal - December 14, 2014 Category: Cardiology Authors: Lip, G. Y. H., Laroche, C., Ioachim, P. M., Rasmussen, L. H., Vitali-Serdoz, L., Petrescu, L., Darabantiu, D., Crijns, H. J. G. M., Kirchhof, P., Vardas, P., Tavazzi, L., Maggioni, A. P., Boriani, G. Tags: Fast Track ESC Clinical Trial and Registry Update Source Type: research

Association between pre-operative statin use and major cardiovascular complications among patients undergoing non-cardiac surgery: the VISION study
Conclusion Among patients undergoing non-cardiac surgery, pre-operative statin therapy was independently associated with a lower risk of cardiovascular outcomes at 30 days. These results require confirmation in a large randomized trial. Clinical trial registration Clinical Trials.gov NCT00512109
Source: European Heart Journal - January 7, 2016 Category: Cardiology Authors: Berwanger, O., Le Manach, Y., Suzumura, E. A., Biccard, B., Srinathan, S. K., Szczeklik, W., Santo, J. A. E., Santucci, E., Cavalcanti, A. B., Archbold, R. A., Devereaux, P. J., for the VISION Investigators Tags: ESC Clinical Registry Source Type: research

Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study
Conclusions  Larger early LDL-C reduction and more intensive statin therapy after MI were associated with a reduced hazard of all CV outcomes and all-cause mortality. This supports clinical trial data suggesting that earlier lowering of LDL-C after an MI confers the greatest benefit.
Source: European Heart Journal - December 24, 2020 Category: Cardiology Source Type: research

Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences
Conclusion A substantial proportion of people do not adhere adequately to cardiovascular medications, and the prevalence of suboptimal adherence is similar across all individual CVD medications. Absolute and relative risk assessments demonstrate that a considerable proportion of all CVD events (~9% in Europe) could be attributed to poor adherence to vascular medications alone, and that the level of optimal adherence confers a significant inverse association with subsequent adverse outcomes. Measures to enhance adherence to help maximize the potentials of effective cardiac therapies in the clinical setting are urgently required.
Source: European Heart Journal - October 7, 2013 Category: Cardiology Authors: Chowdhury, R., Khan, H., Heydon, E., Shroufi, A., Fahimi, S., Moore, C., Stricker, B., Mendis, S., Hofman, A., Mant, J., Franco, O. H. Tags: Prevention and epidemiology Source Type: research

Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure
Conclusions Use of ACEI/ARB was not associated with better outcomes in stable CAD outpatients without HF. The benefit of ACEI/ARB seen in randomized clinical trials was not replicated in this large contemporary cohort, which questions their value in this specific subset.
Source: European Heart Journal - July 7, 2014 Category: Cardiology Authors: Sorbets, E., Labreuche, J., Simon, T., Delorme, L., Danchin, N., Amarenco, P., Goto, S., Meune, C., Eagle, K. A., Bhatt, D. L., Steg, P. G. Tags: Coronary artery disease Source Type: research

Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial
ConclusionAlthough intensive lowering with standard pitavastatin plus ezetimibe showed no more cardiovascular benefit than standard pitavastatin monotherapy in ACS patients with dyslipidaemia, statin plus ezetimibe may be more effective than statin monotherapy in patients with higher cholesterol absorption; further confirmation is needed.Trial NoUMIN000002742, registered as an International Standard Randomized Controlled Trial.
Source: European Heart Journal - April 18, 2017 Category: Cardiology Source Type: research